MAP2K7 and lung cancer: As shown in Fig. 2A, pharmacologic interactions between the two agents were almost invariably synergistic in cells with PTEN-loss, while combined MEK/mTOR inhibition resulted in a slightly additive/frankly antagonistic growth inhibitory response in PTEN-competent tumor cells, with the notable exception of the H460 lung cancer cell line, where combined treatment achieved strongly synergistic growth inhibition, despite the presence of an intact PTEN gene and protein.